Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TWST | CLUSTER | neutral | 4/10 | Twist Bioscience CEO Emily Leproust and CFO Adam Laponis sold a combined $345K in shares over the past week, with the ma | Apr 23, 2026 |
| PACB | PRESS-RELEASE | neutral | 3/10 | PacBio announced that Lucid Genomics has joined its PacBio Compatible partner program, integrating its cloud-native bioi | Apr 21, 2026 |
| CRSP | DEFA14A | neutral | 3/10 | CRISPR Therapeutics AG filed a definitive proxy statement for its 2026 Annual General Meeting, seeking shareholder appro | Apr 21, 2026 |
| DNA | CLUSTER | bearish | 6/10 | Four insiders, including executives and a 10% owner, sold $2.52M in shares over a 7-day period, with open-market sales a | Apr 20, 2026 |
| BEAM | DEFA14A | neutral | 3/10 | Beam Therapeutics Inc. (BEAM) has filed its definitive proxy statement (DEFA14A) for the 2026 annual meeting. The filing | Apr 17, 2026 |
| PACB | PRESS-RELEASE | neutral | 1/10 | PacBio announced it will report its Q1 2026 results on May 7, 2026. | Apr 16, 2026 |
| DNA | CLUSTER | bearish | 6/10 | Three corporate insiders at Ginkgo Bioworks (DNA) conducted open-market share sales over a 7-day period, totaling approx | Apr 13, 2026 |
| RXRX | CLUSTER | neutral | 3/10 | Two directors at Recursion Pharmaceuticals sold a combined $217K in shares over a 7-day window, with no open-market buyi | Apr 8, 2026 |
| DNABW | 8-K | neutral | 5/10 | Ginkgo Bioworks completed the disposition of its Biosecurity segment to Tower Biosecurity, Inc. in exchange for a 20% eq | Apr 7, 2026 |
| EDIT | 8-K | neutral | 3/10 | Editas Medicine dismissed Ernst & Young as its auditor and appointed PricewaterhouseCoopers (PwC) effective April 1, 202 | Apr 7, 2026 |
| NTLA | PRESS-RELEASE | neutral | 2/10 | Intellia Therapeutics granted inducement RSUs covering 67,150 shares to 13 new employees outside its shareholder-approve | Apr 3, 2026 |
| ILMN | 8-K | neutral | 3/10 | Illumina announced that three board members—Drs. Frances Arnold, Robert S. Epstein, and Gary S. Guthart—will retire at t | Apr 2, 2026 |
| RXRX | CLUSTER | neutral | 3/10 | Director Christopher Gibson sold 40,000 shares in an open-market transaction for $130,000, while also converting derivat | Mar 25, 2026 |
| RXRX | PRESS-RELEASE | neutral | 3/10 | Recursion Pharmaceuticals announced the appointment of Dr. Vicki Goodman as its new Chief Medical Officer, effective Apr | Mar 25, 2026 |
| BEAM | PRESS-RELEASE | bullish | 8/10 | Beam Therapeutics announced updated Phase 1/2 data for BEAM-302, a base-edited therapy for alpha-1 antitrypsin deficienc | Mar 25, 2026 |
| CRSP | CLUSTER | neutral | 3/10 | CRISPR Therapeutics CFO Prasad Raju sold $173,460 worth of shares in an open-market transaction, while both the CFO and | Mar 24, 2026 |
| TWST | CLUSTER | neutral | 3/10 | Three insiders at Twist Bioscience sold shares in a coordinated open-market transaction on March 20, 2026, including CEO | Mar 24, 2026 |
| BNGO | PRESS-RELEASE | bearish | 6/10 | Bionano Genomics reported Q4 and full-year 2025 results with declining revenue and net losses, though gross margins and | Mar 23, 2026 |
| TWST | CLUSTER | bearish | 5/10 | Three insiders at Twist Bioscience sold shares in a coordinated 7-day window, including CEO Emily Leproust, who sold $11 | Mar 10, 2026 |
| NTLA | PRESS-RELEASE | neutral | 3/10 | Intellia Therapeutics granted inducement awards of 16,500 RSUs to six new employees outside its shareholder-approved equ | Mar 6, 2026 |
| BEAM | 8-K | neutral | 4/10 | Beam Therapeutics Inc. (BEAM) and Bio Palette Co., Ltd. mutually terminated their 2019 License Agreement due to Bio Pale | Mar 5, 2026 |
| PACB | CLUSTER | neutral | 3/10 | A cluster of insider transactions at Pacific Biosciences of California (PACB) over the past week consists primarily of n | Mar 5, 2026 |
| PACB | 8-K | neutral | 3/10 | Pacific Biosciences appointed Christopher Gibson, Ph.D., to its Board of Directors and Science and Technology Committee, | Mar 5, 2026 |
| TXG | CLUSTER | neutral | 4/10 | 10x Genomics CEO Saxonov sold $324K in open-market shares while receiving a large non-cash stock award; CFO and another | Mar 4, 2026 |
| NTLA | CLUSTER | neutral | 3/10 | Intellia Therapeutics insiders executed a mix of open-market sales and stock awards over the past week. Two executives s | Mar 3, 2026 |
| TXG | CLUSTER | neutral | 3/10 | A recent insider trading cluster at 10x Genomics includes a non-cash share award to CFO Taich Adam and an open-market sa | Mar 2, 2026 |
| NTLA | PRESS-RELEASE | bullish | 8/10 | Intellia Therapeutics announced that the FDA has lifted the clinical hold on its Phase 3 MAGNITUDE trial for nexiguran z | Mar 2, 2026 |
| NTLA | INST-CLUSTER | neutral | 4/10 | Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — significantly increased their positions in Int | Feb 28, 2026 |
| PACB | INST-CLUSTER | bullish | 7/10 | Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — significantly increased their posit | Feb 28, 2026 |
| TXG | CLUSTER | bearish | 6/10 | Four insiders at 10x Genomics sold shares in the past week, including CEO Serge Saxonov and CFO Adam Taich, with total o | Feb 27, 2026 |